Short answer
CareDx, Inc. (CDNA) filed an 8-K current report with the SEC on July 7, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure). CareDx received $171.7 million cash from Eurobio for CareDx AB and kitted laboratory products assets.
CareDx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- CareDx received $171.7 million cash from Eurobio for CareDx AB and kitted laboratory products assets
- Divestiture removes the kitted laboratory products business and related software from CareDx’s portfolio
- CareDx acquired Naveris for $161.8 million cash, subject to customary purchase-price adjustments
- Naveris sellers may receive up to $100.0 million additional cash tied to 2026 and 2027 revenue milestones
- Transactions completed June 30 and July 1, 2026, reshaping CareDx’s business mix and capital allocation profile
Item 7.01 · Regulation FD Disclosure
- CareDx announced closing of the Eurobio Transaction on June 30, 2026
- CareDx announced closing of the Naveris Transaction on July 1, 2026
- Transaction details and expected financial impact are contained in Exhibits 99.1 and 99.2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CareDx, Inc. 8-K filings
Get the next CDNA 8-K as it lands
Follow CDNA for push alerts, or ask the research agent what this filing means.